OKYO Pharma Taps Flavio Mantelli to Lead Phase I ADC Trials
OKYO Pharma appointed Flavio Mantelli as chief medical officer effective April 1, 2026, tapping his 18 years leading oncology clinical programs at Novartis and Incyte. He will oversee the company’s Phase I antibody-drug conjugate candidate for solid tumors and shape clinical strategy ahead of planned Phase II trials.
1. Appointment Details
On April 1, 2026, OKYO Pharma named Flavio Mantelli as chief medical officer. In this role, he will direct all clinical development activities and advance regulatory filings for the company’s oncology pipeline.
2. Professional Background
Mantelli brings 18 years of oncology R&D experience, most recently as Head of Clinical Development at Incyte and previously leading translational medicine teams at Novartis. He has managed multiple IND submissions and Phase I–III trials in solid tumors.
3. Strategic Impact
His expertise will focus on OKYO’s Phase I antibody-drug conjugate candidate targeting solid tumors, guiding its transition into Phase II studies. The appointment aims to strengthen clinical leadership as OKYO prepares for key trial milestones next year.